BURLINGTON, Mass., April 17, 2014 /PRNewswire/ -- Decision Resources Group finds that the novel oral anticoagulants (NOACs) will dramatically alter the treatment landscape for VTE treatment and secondary prophylaxis. Surveyed emergency room physicians and cardiologists indicate that they currently use Bayer/Janssen's Xarelto in 14 percent and 31 percent of their patients respectively, with over two-thirds of surveyed physicians increasing their use of Xarelto by 2015. Physicians indicate that Bristol-Myers Squibb/Pfizer's Eliquis is expected to garner a 19 percent patient share in 2015. Use of Boehringer Ingelheim's Pradaxa and Daiichi Sankyo's Savaysa are also expected to garner double-digit patient share in 2015, despite the requirement for preceding use of an injectable anticoagulant.

Other key findings from the U.S. Physician and Payer Forum report entitled U.S. Uptake of the Novel Oral Anticoagulants in Venous Thromboembolism: Impact of Physicians and Payers on Prescribing?:

• Physicians indicate that they are unwilling to increase the duration of therapy for the treatment of either deep vein thrombosis or pulmonary embolism, despite extension studies demonstrating the NOACs' safety with extended duration therapy.
• Despite low patient numbers in clinical trials, physicians express willingness to prescribe the NOACs for treatment of VTE in cancer patients.
• One in three MCOs will not reimburse Savaysa if priced at the same level as Xarelto. Savaysa will have to be priced at a significant discount to Xarelto in order to gain favorable tier placement, despite demonstrating a significant reduction in bleeding compared to the standard of care.
• Despite the emergence of the NOACs, warfarin is expected to remain the patient share leader in 2015, although physicians expect to use warfarin less frequently than at present. Warfarin's preferred status on almost three-quarters of commercial healthcare plans is a major contributing factor to its continued dominance.

Comments from Decision Resources Group Analyst Dr. Eamonn O'Connor, Ph.D.:

• "Xarelto's first-to-market advantage for the treatment of VTE registers more highly with both physicians and payers than the demonstrated reductions in bleeding compared to standard of care seen with the other NOACs (Xarelto did not demonstrate reduced bleeding compared with standard of care) when estimating future patient share and formulary placement respectively."
• "The added convenience offered by Xarelto and Eliquis (no requirement for preceding use of an injectable anticoagulant) did not impact on anticipated use or reimbursement of Pradaxa, Savaysa, or standard of care as much as anticipated. This may reflect concerns over ensuring patients are adequately anticoagulated in the acute treatment phase. A number of physicians indicated use of Xarelto after preceding injectable therapy use, despite not being indicated for use in this manner."

Upcoming webinar:

Media members are welcome to attend our upcoming webinar based on this report entitled Novel Oral Anticoagulants: A Wider Range of Choices Requires Specific Market Positioning. This presentation will be held on Tuesday, May 20, 2014. For more information, please contact Christopher Comfort at [email protected].

Additional Resources:

• Dr. Eamonn O'Connor has written a related blog on the subject, which can be found here.

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or
registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
[email protected]

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources